Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis

Inventors

Totaro, Kyle A. • Simon, Mark D. • Zhou, Ming • Zong, Hong • Hanson, Gunnar J. • Pentelute, Bradley L.

Assignees

Massachusetts Institute of Technology • Sarepta Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12590306-B2

Patent

Publication Date

2026-03-31

Expiration Date


Abstract

Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomersynthesis while maintaining overall yield and purity of a synthesized oligomer.

Core Innovation

The invention provides a process for preparing an oligomeric compound of Formula (I), where n is an integer from 9 to 39 and T is OH. The process comprises sequential steps using compounds of Formula (A1), (A2), (A3), (A4), and (A8) to form intermediates of Formula (II), (IV), (A5), (A9), (A10), and (A11), with support-medium B or R1 as a support-medium and R3 selected from trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl.

A central feature is the use of deblocking and contacting steps combined with a Lewis acid catalyst. The process includes contacting a compound of Formula (A1) with a deblocking agent to form Formula (II), contacting Formula (II) with Formula (A2) to form Formula (A3), contacting Formula (A3) with a deblocking agent to form Formula (IV), and contacting Formula (IV) with Formula (A4) in the presence of a Lewis acid catalyst to form Formula (A5).

The process further performs Y iterations of sequential deblocking and contacting with Formula (A8) in the presence of a Lewis acid catalyst to form Formula (A9), where Y is n−1 if R7 is of Formula (A5a) and n−2 if R7 is of Formula (A5b). After the iterations, the sequence continues with deblocking to form Formula (A10), cleaving to form Formula (A11), and deprotecting to form the oligomeric compound of Formula (I).

The process permits any of steps (a), (b), (c), (d), (e1), (e2), (f), (g), or (h) to be carried out in a continuous synthesis. In described embodiments, continuous synthesis is supported by a flow-through reactor approach, and the process uses a PMO synthesis resin reaction zone for sequential deblocking and Lewis-acid-catalyzed contacting steps.

Claims Coverage

One independent claim, clm-00001, covers a sequential process for preparing an oligomeric compound of Formula (I) with n from 9 to 39 and T=OH, using deblocking, Lewis acid-catalyzed contacting, Y iterations tied to R7, and final cleaving and deprotecting, with an option for continuous synthesis.

Sequential deblocking-to-coupling synthesis of oligomer intermediates

A process that contacts Formula (A1) with a deblocking agent to form Formula (II), contacts Formula (II) with Formula (A2) to form Formula (A3), contacts Formula (A3) with a deblocking agent to form Formula (IV), and contacts Formula (IV) with Formula (A4) in the presence of a Lewis acid catalyst to form Formula (A5).

Defined substituent and support-medium selections

The process constrains support-medium B or R1 as a support-medium and selects R3 from trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl, with defined R4, R5, R6, R7, R8, and R9 selections through the sequence.

Y-iteration cycle linking deblocking to Formula (A8) coupling

The process performs Y iterations of sequential steps (e1) contacting the product formed by the immediately prior step with a deblocking agent and (e2) contacting the compound formed by the immediately prior step with a compound of Formula (A8) in the presence of a Lewis acid catalyst, where Y is n−1 if R7 is of Formula (A5a) and n−2 if R7 is of Formula (A5b).

Final cleaving and deprotecting to form Formula (I)

After forming Formula (A9), the process contacts Formula (A9) with a deblocking agent to form Formula (A10), contacts Formula (A10) with a cleaving agent to form Formula (A11), and contacts Formula (A11) with a deprotecting agent to form the oligomeric compound of Formula (I).

Continuous synthesis option for specified steps

Any of steps (a), (b), (c), (d), (e1), (e2), (f), (g), or (h) are carried out in a continuous synthesis.

The claim coverage centers on a constrained, stepwise synthesis of an oligomeric compound of Formula (I) with n from 9 to 39, combining deblocking, Lewis acid-catalyzed contacting, Y iterations based on R7, and final cleaving and deprotecting, with an explicit continuous synthesis option.

Stated Advantages

Fast-flow continuous synthesis for PMO synthesis.

Documented Applications

PMO synthesis.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.